Skip to main content
. 2023 Jan 3;91(1):245–261. doi: 10.3233/JAD-220764

Table 2.

Diagnosis, radiology, history, PUFA supplementation, and cognitive results. Patients are listed by accession number and show clinical diagnosis (Dx), radiology (PET and MRI), history and symptoms, cholinesterase inhibitor (CI) (Aricept) and NMDA blocker (Namenda) therapy, MMSE score at the first and the last visit, onset of dementia, and duration of PUFA supplementation by the SmartfishR drink (SMF) (months)

Subjective Cognitive Impairment
Months on AD Therapy MMSE Score
Pt # Dx Radiology History CI NMDA First Visit Last Visit Onset of Dementia (mo p onset) PUFA supplement (mo)
8 SCI N/D Memory loss 0 0 30 30 neg 24
10 SCI N/D Memory loss, familial alcoholism 0 0 29 30 neg 24
18 SCI N/D Concussion, low exec. function 2 2 30 30 neg 56
Mild Cognitive Impairment (MCI)
22 MCI N/D Memory loss 24 24 22 24 neg 25
28 MCI No stenosis (MRA) Memory loss 24 0 16 25 neg >19
MCI/Vascular Cognitive Impairment (VCI)
2 VCI Regional hypo metabolism (PET) Repeated minor strokes 0 24 24 27 Neg 44
14 VCI Post cingulate hypometabolism (PET) Repeated minor strokes 24 0 25 27 60 49
37 VCI Assymetric temporal hypometabolism Depression 0 0 30 30 Neg 36
Dementia with Lewy Bodies (DLB)/ VCI
9 DLB Cortical hypometabolism (PET) Paranoia 0 0 26 25 24 22
33 DLB Parieto-temporal, cingulate and visual cortex hypometabolism (PET) Major depression 12 12 26 30 Neg 36